Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 7:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Mitochondrial Disorders Clear all
Completed Phase 3 Interventional

A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS

NCT00000688
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
22
States / cities
San Diego, California • San Francisco, California • San Mateo, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2011 · Synced Sep 23, 2026, 7:30 AM EDT
Terminated Phase 1 Interventional

A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia

NCT06681766
View directory record Official record
Conditions
Friedreich Ataxia
Interventions
Nomlabofusp, Placebo
Drug
Lead sponsor
Larimar Therapeutics, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chevy Chase, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 23, 2026, 7:30 AM EDT
Completed Phase 4 Interventional Results available

CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL")

NCT01552369
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
Valganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
6
States / cities
Los Angeles, California • Atlanta, Georgia • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Sep 23, 2026, 7:30 AM EDT
Recruiting Phase 1 Interventional

Triheptanoin for Children With Primary-Specific Pyruvate Dehydrogenase Complex (PDC) Deficiency

NCT06340685
View directory record Official record
Conditions
Pyruvate Dehydrogenase Complex Deficiency
Interventions
Triheptanoin
Drug
Lead sponsor
Jirair Krikor Bedoyan
Other
Eligibility
1 Year to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 23, 2026, 7:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of MitoQ on Platelet Function and Reactive Oxygen Species Generation in Patients With Sickle Cell Anemia

NCT04109820
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
MitoQ
Dietary Supplement
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
5
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 23, 2026, 7:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy

NCT01537549
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
alpha-lipoic acid and L-acetyl carnitine
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
40 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 23, 2026, 7:30 AM EDT
Completed Phase 1 Interventional

A Phase I Pharmacokinetic and Tolerance Study of 28-Day Regimens of Oral Ganciclovir

NCT00000668
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
5
States / cities
San Diego, California • San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 23, 2026, 7:30 AM EDT
Completed Phase 1 Interventional

Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia

NCT05573698
View directory record Official record
Conditions
Friedreich Ataxia
Interventions
DT-216, Placebo
Drug
Lead sponsor
Design Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Sep 23, 2026, 7:30 AM EDT
Completed Phase 1 Interventional

A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis

NCT00002321
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
Chiron Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 23, 2026, 7:30 AM EDT
Completed Phase 2 Interventional

EPI-743 in Friedreich's Ataxia Point Mutations

NCT01962363
View directory record Official record
Conditions
Friedreich's Ataxia
Interventions
EPI-743
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Sep 23, 2026, 7:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Biologic Mechanisms for Pain Variation After Physical Activity in Osteoarthritis

NCT03344913
View directory record Official record
Conditions
Osteoarthritis, Knee, Pain, Physical Activity, Mitochondrial Pathology
Interventions
Walking
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
50 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced Sep 23, 2026, 7:30 AM EDT
Not yet recruiting Phase 3 Interventional

Long-Term Efficacy Study of Vatiquinone for the Treatment of Friedreich's Ataxia (FA)

NCT07681713
View directory record Official record
Conditions
Friedreich's Ataxia
Interventions
Vatiquinone
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
7 Years to 21 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Los Angeles, California • Tampa, Florida • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 23, 2026, 7:30 AM EDT
Terminated Phase 2Phase 3 Interventional

Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia

NCT00803868
View directory record Official record
Conditions
Friedreich's Ataxia
Interventions
varenicline, placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Tampa, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 23, 2012 · Synced Sep 23, 2026, 7:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy

NCT02367014
View directory record Official record
Conditions
Mitochondrial Myopathy
Interventions
elamipretide (low dose), elamipretide (intermediate dose), elamipretide (high dose), Placebo
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
16 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
San Diego, California • Boston, Massachusetts • Akron, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Sep 23, 2026, 7:30 AM EDT
Completed Phase 2 Interventional Results available

The Use of a Mitochondrial Enhancement Treatment in Bipolar Disorder

NCT00719706
View directory record Official record
Conditions
Bipolar Depression
Interventions
acetyl-l-carnitine PLUS alpha-lipoic acide, Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 17, 2012 · Synced Sep 23, 2026, 7:30 AM EDT
No Longer Available No phase listed Expanded access

EPI-743 for Mitochondrial Respiratory Chain Diseases

NCT01370447
View directory record Official record
Conditions
Mitochondrial Diseases
Interventions
EPI-743
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
1 Year and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
16
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2024 · Synced Sep 23, 2026, 7:30 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy

NCT04641962
View directory record Official record
Conditions
Primary Mitochondrial Myopathy
Interventions
Bocidelpar, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
11
States / cities
La Jolla, California • Stanford, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 23, 2026, 7:30 AM EDT
Completed No phase listed Observational

A Retrospective Study of Subjects With Thymidine Kinase 2 Deficiency

NCT05017818
View directory record Official record
Conditions
Thymidine Kinase 2 Deficiency
Interventions
Observational retrospective data
Other
Lead sponsor
Zogenix MDS, Inc.
Industry
Eligibility
Not listed
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Los Angeles, California • Indianapolis, Indiana • Akron, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Sep 23, 2026, 7:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Mitochondrial Function in Circulating Cells and Muscle Tissue

NCT02700698
View directory record Official record
Conditions
Healthy, Obesity, Insulin Sensitivity, Women
Interventions
Not listed
Lead sponsor
University of Arkansas
Other
Eligibility
25 Years to 35 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Sep 23, 2026, 7:30 AM EDT
Active, not recruiting Not applicable Interventional

Home Based Tele-exercise for People With Chronic Neurological Impairments

NCT04564495
View directory record Official record
Conditions
Neurologic Disorder, Stroke, Spinal Cord Injuries, Cerebral Palsy, Hemiplegia, Hemiparesis, Multiple Sclerosis, Parkinson Disease, Trauma, Brain, Transverse Myelitis, Friedreich Ataxia
Interventions
Seated exercise
Behavioral
Lead sponsor
Burke Medical Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
White Plains, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Sep 23, 2026, 7:30 AM EDT
Recruiting Not applicable Interventional

Stem Cell Ophthalmology Treatment Study II

NCT03011541
View directory record Official record
Conditions
Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease, Optic Neuropathy, Nonarteritic Ischemic Optic Neuropathy, Optic Atrophy, Optic Nerve Disease, Glaucoma, Leber Hereditary Optic Neuropathy, Blindness, Vision Loss Night, Vision Loss Partial, Vision, Low, Retinopathy, Maculopathy, Macular Degeneration, Retina Atrophy
Interventions
Arm 1
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
2
States / cities
Westport, Connecticut • Coral Springs, Florida
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 23, 2026, 7:30 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Effects of an Antioxidant Supplement on Blood Vessel Health

NCT06424756
View directory record Official record
Conditions
Healthy
Interventions
MitoQ, Placebo, MitoTempo, Tempol, L-NAME, SNP - Sodium Nitroprusside
Dietary Supplement · Drug
Lead sponsor
University of Georgia
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
1
States / cities
Athens, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 8, 2024 · Synced Sep 23, 2026, 7:30 AM EDT
Completed Phase 1 Interventional

Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients

NCT01064505
View directory record Official record
Conditions
Optic Atrophy, Non-arteritic Anterior Ischemic Optic Neuropathy
Interventions
QPI-1007 at various doses
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
22
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 12, 2013 · Synced Sep 23, 2026, 7:30 AM EDT
Completed Phase 3 Interventional

Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV

NCT00006145
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Valganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
56
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 23, 2026, 7:30 AM EDT